NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today its participation in two upcoming medical industry conferences, underscoring its commitment to advancing surgical care for neurological disorders. The company will attend the American Epilepsy Society (AES) 2025 Annual Meeting in Atlanta, GA, from December 5th to December 9th, and the CNS Drug Delivery Summit in Boston, MA, from December 9th to 11th.
The AES Annual Meeting, details of which are available at AES Annual Meeting Registration, brings together healthcare providers, scientists, advocates, and industry professionals dedicated to improving outcomes for people with epilepsy. This event provides a platform for NeuroOne to showcase its minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, and drug delivery, which are designed to enhance surgical precision and patient recovery.
Following the AES meeting, NeuroOne will participate in the CNS Drug Delivery Conference in Boston. This summit gathers over 100 industry experts, including neuroscientists, chemists, device engineers, and delivery specialists, to collaborate on strategies for overcoming challenges in accessing the brain for drug delivery. NeuroOne's presence at this conference highlights its potential applications in treating conditions such as Parkinson’s disease, essential tremors, chronic pain, and other neurological disorders.
The company's technology focuses on improving patient outcomes and reducing procedural costs. NeuroOne’s portfolio includes solutions for epilepsy, movement disorders, and chronic pain, with potential future applications in depression, mood disorders, incontinence, and artificial intelligence. The conferences offer opportunities for NeuroOne to engage with key opinion leaders and explore partnerships that could accelerate the adoption of its technologies.
For more information about NeuroOne and its product pipeline, visit nmtc1.com. The company’s participation in these events signals its active role in shaping the future of neurological care through innovation and collaboration.
